Epic Sciences announces presentation of three studies on novel CTC liquid biopsy assays for metastatic prostate cancers and bladder cancers at 2015 SACO GU Cancer Symposium.

Circulating tumor cell analysis provides comprehensive information from a real-time liquid biopsy that could help guide treatments fror metastatic prostate cancers and bladder cancers.

Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic’s circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium which will be held February 26 to 28 at Rosen Shingle Creek in Orlando, Fla. Epic is developing highly informative diagnostic tests that can detail the dynamic changes in gene and protein expression that occur during the course of cancer treatments to inform therapeutic development, therapy selection and drug resistance mechanisms.

“A major unmet medical need in treating metastatic cancers is in the identification of predictive biomarkers for therapeutic efficacy, disease heterogeneity and drug resistance in the context of key clinical decision points,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. “The studies to be presented by our collaborators at ASCO GU demonstrate the diagnostic and predictive capabilities of Epic’s CTC technology across multiple metastatic cancers in the pursuit of developing actionable liquid biopsy biomarkers to guide treatment decisions. We look forward to advancing and validating these CTC liquid biopsy assays for clinical use.”

From a simple blood test, Epic’s “no cell left behind” technology applies a global, unbiased approach to approximately six million cells across more than 90 parameters to capture and analyze all possible types of CTCs. This information can be used to compile a comprehensive picture of a patient’s cancer to guide treatment choices.

2015 ASCO GU Poster Presentations:

1. Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (Abstract 147)

Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)

Highlight: Selected for Audio Poster Tour

2. Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC. (Abstract 197)

Thursday 11:30 am to 1:00 pm and 5:15 pm to 6:45 pm EST (Poster Session A)

3. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle-invasive (MIBC) and metastatic bladder cancer (mBCa) patients. (Abstract 353)

Friday 12:15 pm to 1:45pm and 6:00 pm to 7:00 pm (Poster Session B)

About Epic Sciences

At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.

We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.

For more information, visit

Stay in touch on LinkedIn, on Twitter@EpicSciences and

Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc.,,+1.858.344.8091